NCT05827978

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

A Phase 3, Randomized, Stratified, Observer-Blind, Active-Controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 18 Years and Older

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 8,411 (actual)
• Sponsor: ModernaTX, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.

Conditions

• Seasonal Influenza

Interventions

Type	Name	Description
BIOLOGICAL	mRNA-1010	Sterile liquid for injection
BIOLOGICAL	Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine	Sterile suspension for injection

Timeline

• Start date: 2023-04-17
• Primary completion: 2024-06-24
• Completion: 2024-06-24
• First posted: 2023-04-25
• Last updated: 2025-07-10
• Results posted: 2025-07-10

Locations

103 sites across 1 country: United States

Regulatory

• FDA-regulated drug study